Document Detail


Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo.
MedLine Citation:
PMID:  20535833     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of our study was to investigate the effect of biochanin A on the accumulation and transport of mitoxantrone in breast cancer resistance protein (BCRP)-expressing normal cells and its impact on the pharmacokinetics (PK) and tissue distribution of mitoxantrone. In accumulation studies, the intracellular level of mitoxantrone was significantly increased in the presence of 2.5 or 25 microM of biochanin A in both murine and human BCRP-expressing Madin-Darby canine kidney (MDCK) cells, with no effect in corresponding MDCK/Mock cells. In bi-directional transport studies, the P(app,B-A) value of mitoxantrone with biochanin A co-treatment was much lower (6.66+/-0.84x10(-7) cm/s) than that in the absence of biochanin A (21.4+/-4.14x10(-7) cm/s), indicating inhibition of Bcrp1-mediated efflux. To evaluate whether our in vitro results might translate into an in vivo interaction, mitoxantrone PK and tissue distribution, with and without co-administration of biochanin A, was investigated. In contrast to our in vitro results, biochanin A (10 mg/kg, i.v.) had no impact on the concentration of mitoxantrone in plasma and most tissues collected (brain, heart, liver and lung). Surprisingly, the concentrations of mitoxantrone in spleen and kidney were even decreased when biochanin A was co-administered. Interestingly, it was found that the intracellular fluorescence of mitoxantrone was decreased 31.9% when co-incubated with 10 microM biochanin A in P-glycoprotein (P-gp) expressing MCF-7/ADR cells, indicating potential P-gp stimulation. The species difference of the inhibitory effect of biochanin A on BCRP, the extensive metabolism of biochanin A, as well as the stimulation effect of biochanin A on P-gp, may contribute to this in vitro-in vivo disconnect.
Authors:
Guohua An; Marilyn E Morris
Related Documents :
10375743 - Menadione reduced doxorubicin resistance in ehrlich ascites carcinoma cells in vitro.
8690513 - Cellular pharmacology of idarubicinol in multidrug-resistant lovo cell lines.
12210493 - Resveratrol induces apoptosis in lncap cells and requires hydroxyl groups to decrease v...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biopharmaceutics & drug disposition     Volume:  31     ISSN:  1099-081X     ISO Abbreviation:  Biopharm Drug Dispos     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-01     Completed Date:  2010-10-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7911226     Medline TA:  Biopharm Drug Dispos     Country:  England    
Other Details:
Languages:  eng     Pagination:  340-50     Citation Subset:  IM    
Copyright Information:
2010 John Wiley & Sons, Ltd.
Affiliation:
Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Amherst, 14260, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / pharmacokinetics*
Biological Transport / drug effects*
Cell Line, Transformed
Cell Line, Tumor
Dose-Response Relationship, Drug
Drug Combinations
Drug Interactions
Drug Resistance, Neoplasm / drug effects
Flavonoids / pharmacology*
Genistein / administration & dosage,  pharmacology*
Humans
Male
Mice
Mitoxantrone / administration & dosage,  pharmacokinetics*
Tissue Distribution / drug effects*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Drug Combinations; 0/Flavonoids; 446-72-0/Genistein; 491-80-5/biochanin A; 65271-80-9/Mitoxantrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Estimating the extra cost of living for people with disabilities.
Next Document:  Prevalence of the fibrinogen beta-chain, angiotensin-converting enzyme and plasminogen activator inh...